Walleye Capital
SRPT icon

Walleye Capital’s Sarepta Therapeutics SRPT Stock Holding History

Walleye Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$516K Sell
28,700
-27,100
-49% -$513K ﹤0.01% 2708
2026
Q1 		$1.21M Sell
55,800
-9,100
-14% -$176K 0.01% 1899
2025
Q4 		$1.4M Buy
64,900
+9,000
+16% +$190K ﹤0.01% 2170
2025
Q3 		$1.08M Sell
55,900
-135,600
-71% -$2.42M ﹤0.01% 2033
2025
Q2 		$3.27M Buy
191,500
+190,900
+31,817% +$8.14M 0.01% 1146
2025
Q1 		$38.3K Sell
600
-10,300
-94% -$1.08M ﹤0.01% 3911
2024
Q4 		$1.33M Sell
10,900
-15,900
-59% -$1.95M ﹤0.01% 2135
2024
Q3 		$3.35M Buy
26,800
+2,000
+8% +$276K 0.01% 1483
2024
Q2 		$3.92M Buy
24,800
+13,900
+128% +$1.79M 0.01% 1480
2024
Q1 		$1.41M Buy
10,900
+6,800
+166% +$833K ﹤0.01% 2257
2023
Q4 		$395K Sell
4,100
-2,800
-41% -$269K ﹤0.01% 3126
2023
Q3 		$836K Sell
6,900
-15,300
-69% -$1.73M ﹤0.01% 2405
2023
Q2 		$2.54M Sell
22,200
-2,700
-11% -$348K 0.01% 1174
2023
Q1 		$3.43M Buy
24,900
+11,200
+82% +$1.45M 0.05% 451
2022
Q4 		$1.78M Sell
13,700
-6,600
-33% -$765K 0.03% 651
2022
Q3 		$2.24M Buy
+20,300
New +$2.05M 0.04% 491
2020
Q1 		– Sell
-20,800
Closed -$2.68M – 1591
2019
Q4 		$2.68M Buy
20,800
+7,500
+56% +$757K 0.17% 140
2019
Q3 		$1M Buy
+13,300
New +$1.57M 0.06% 456

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Walleye Capital's SRPT Position: Q2 2026 in Review

Walleye Capital reduced its Sarepta Therapeutics (SRPT) stake by 88% in Q2 2026, selling an estimated $4.81M and leaving 34,421 shares worth $619K. The position accounts for ﹤0.01% of the portfolio, ranked #2535.

Walleye Capital first reported a position in SRPT in Q2 2019 and has held it in 20 quarters since. The position peaked at $10.5M in Q4 2023. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Walleye Capital held 34,421 shares of Sarepta Therapeutics worth $619K as of Q2 2026.
  • Walleye Capital sold 254,111 Sarepta Therapeutics shares in Q2 2026, an estimated $4.81M.
  • Sarepta Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #2535 holding.
  • Walleye Capital first reported a position in Sarepta Therapeutics in Q2 2019 and has held it in 20 quarters since.
  • Walleye Capital's Sarepta Therapeutics position peaked at $10.5M in Q4 2023.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.